Skip to Main Content

Advertisement

Skip Nav Destination

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Blood (2012) 120 (25): 5084–5085.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement